Mohan P, Safi K, Little D M, Donohoe J, Conlon P, Walshe J J, O'Kelly P, Thompson C J, Hickey D P
Department of Transplantation, Nephrology and Dialysis, Beaumont Hospital, Dublin, Ireland.
Br J Surg. 2003 Sep;90(9):1137-41. doi: 10.1002/bjs.4208.
There are emerging data that simultaneous pancreas-kidney transplant (SPK) prolongs life compared with kidney transplant alone (KTA) in type 1 diabetics with end-stage renal disease. This study was a retrospective comparison of SPK with KTA in patients with type 1 diabetes.
Between 1 January 1992 and 30 April 2002, 101 patients with type 1 diabetes were transplanted. Fifty-one of these patients received a KTA and 50 had a SPK. All patients underwent coronary angiography with surgical correction of any coronary artery disease before being listed. All patients who underwent SPK received quadruple immunosuppressive therapy consisting of antilymphocyte globulin, calcineurin inhibitor (tacrolimus or cyclosporin), azathioprine and steroids. Those who underwent KTA received calcineurin inhibitor (tacrolimus or cyclosporin), azathioprine and steroids.
Patient survival at 1, 3, 5 and 8 years was 96, 93, 89 and 77 per cent respectively after SPK, and 93, 75, 57 and 47 per cent respectively after KTA (P = 0.018 at 8 years).
The addition of pancreatic transplantation prolongs life in type 1 diabetic patients with renal failure compared with renal transplantation alone.
有新数据表明,对于患有终末期肾病的1型糖尿病患者,胰肾联合移植(SPK)比单纯肾移植(KTA)能延长寿命。本研究对1型糖尿病患者的SPK和KTA进行了回顾性比较。
在1992年1月1日至2002年4月30日期间,对101例1型糖尿病患者进行了移植。其中51例患者接受了KTA,50例接受了SPK。所有患者在列入移植名单前均接受了冠状动脉造影,并对任何冠状动脉疾病进行了手术矫正。所有接受SPK的患者均接受了由抗淋巴细胞球蛋白、钙调神经磷酸酶抑制剂(他克莫司或环孢素)、硫唑嘌呤和类固醇组成的四联免疫抑制治疗。接受KTA的患者接受钙调神经磷酸酶抑制剂(他克莫司或环孢素)、硫唑嘌呤和类固醇治疗。
SPK后1年、3年、5年和8年的患者生存率分别为96%、93%、89%和77%,KTA后分别为93%、75%、57%和47%(8年时P = 0.018)。
与单纯肾移植相比,胰腺移植可延长1型糖尿病肾衰竭患者的寿命。